Castle Biosciences Q3 revenue beats estimates on TissueCypher volume growth
CSTL•Castle Biosciences’ third-quarter revenue rose 24% year over year to $102.89 million, above the $92.52 million consensus estimate, as TissueCypher test volume grew 47%. The company raised its 2026 revenue guidance to $385 million-$395 million from $365 million-$375 million.
1. Revenue and test volume
Castle Biosciences reported third-quarter revenue of $102.89 million, up 24% year over year and above the $92.52 million analyst consensus. TissueCypher test volume grew 47% year over year, driving the revenue increase.
2. Raised 2026 outlook
The company raised its 2026 revenue guidance to $385 million-$395 million from $365 million-$375 million. It expects positive adjusted EBITDA in the fourth quarter of 2026 and for full-year 2026 and 2027.
3. Quarterly results
Castle reported a net loss of $4.10 million, operating expenses of $105.62 million and an operating loss of $2.73 million. CEO Derek Maetzold attributed results to execution across its test portfolio; the company also cited expense management and operational efficiency.
